NVAX.O
Latest Trade
93.13USDChange
-0.46(-0.49%)Volume
3,106,977Today's Range
-
93.2052 Week Range
-
189.40As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 93.59 |
|---|---|
Open | 92.84 |
Volume | 3,106,977 |
3M AVG Volume | 126.53 |
Today's High | 93.20 |
Today's Low | 86.45 |
52 Week High | 189.40 |
52 Week Low | 3.54 |
Shares Out (MIL) | 61.28 |
Market Cap (MIL) | 5,735.02 |
Forward P/E | -- |
Dividend (Yield %) | -- |
Novavax Appoints Leadership Team To Advance Nanoflu Through Regulatory Licensure
Endo Announces Fill-Finish Manufacturing And Services Agreement For Novavax Covid-19 Vaccine Candidate
Novavax Initiates Phase 3 Efficacy Trial Of COVID-19 Vaccine In The United Kingdom
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
Industry
Biotechnology & Drugs
Contact Info
21 Firstfield Rd
GAITHERSBURG, MD
20878-1757
United States
+1.240.2682000
http://www.novavax.com/Executive Leadership
James Francis Young
Independent Chairman of the Board
Stanley C. Erck
President, Chief Executive Officer, Director
John J. Trizzino
Executive Vice President, Chief Business Officer, Chief Financial Officer and Treasurer
Gregory M. Glenn
President, Research and Development
Jill Hoyt
Chief Human Resource Officer, Executive Vice President
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 114.16 |
Price To Book (MRQ) | 31.05 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 83.60 |
LT Debt To Equity (MRQ) | 83.60 |
Return on Investment (TTM) | -21.52 |
Return on Equity (TTM) | -16.63 |
Novavax Inc said on Tuesday it has set up a team of company veterans as it seeks U.S. regulatory approval for its seasonal influenza vaccine and to help develop a combined influenza/COVID-19 vaccine for use after the pandemic.
Serum Institute of India will make up to 200 million COVID-19 vaccine doses for poorer countries, including India, next year, as the Bill & Melinda Gates Foundation and GAVI vaccines alliance have doubled their funding, the company said on Tuesday.
More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 38 in human trials, according to the World Health Organization (WHO). The following list tracks the latest developments from major drugmakers and research institutes...
Generic drugmaker Endo said on Friday it was manufacturing Novavax Inc's <NVAX.O> experimental COVID-19 vaccine, sending its shares up 10% before the trading bell.
Novavax Inc has signed an agreement with Endo International for manufacturing its experimental COVID-19 vaccine, the generic drugmaker said on Friday.
Novavax Inc <NVAX.O> on Thursday started a late-stage trial of its experimental COVID-19 vaccine in the United Kingdom in partnership with the government's Vaccines Taskforce, sending the company's shares up 6% after the bell.
Novavax Inc on Thursday started a late-stage trial of its experimental COVID-19 vaccine in partnership with the UK government's Vaccines Taskforce.
U.S. drug developer Novavax Inc said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an agreement with Serum Institute of India, sending its shares up about 7%.
Novavax Inc is doubling its COVID-19 vaccine manufacturing capacity to two billion doses under an agreement with Serum Institute of India, the U.S. company said on Tuesday.
Canada reached an agreement in principle on Monday with both Novavax Inc <NVAX.O> and Johnson & Johnson <JNJ.N> for millions of doses of their experimental coronavirus vaccines, Prime Minister Justin Trudeau said.
Novavax Inc said on Monday it had reached an agreement in principle with Canada to supply up to 76 million doses of its experimental coronavirus vaccine.
Novavax Inc expects filing for approval of its COVID-19 vaccine candidate in the United States in December, Chief Executive Stanley Erck said in an interview for Czech daily Hospodarske Noviny, released on Thursday.
Novavax Inc said on Monday it has begun enrolling volunteers for the second phase of an ongoing clinical trial of its COVID-19 vaccine candidate, with interim data expected in the fourth quarter of 2020.
U.S. drug developer Novavax Inc <NVAX.O> said on Monday it started a mid-stage study of its experimental COVID-19 vaccine in South Africa, as the country experiences a surge in coronavirus cases.
* NOVAVAX INITIATES EFFICACY TRIAL OF COVID-19 VACCINE IN SOUTH AFRICA
Britain will buy potential COVID-19 vaccines from U.S. drugmakers Johnson & Johnson <JNJ.N> and Novavax Inc <NVAX.O>, the companies said on Friday, boosting the number of deals it has with drugmakers as the global vaccine race rages on.
U.S. drug developer Novavax Inc <NVAX.O> said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373.
The UK government has sealed two more deals to secure COVID-19 vaccines, buying shots in development from U.S. drugmakers Johnson & Johnson and Novavax Inc, the chair of the UK Vaccine Taskforce Katie Bingham told Sky News on Friday.
Novavax Inc said on Thursday South Korea's SK bioscience would manufacture a component of the U.S. drug developer's experimental coronavirus vaccine in a bid to boost its supply.
Novavax Inc said on Thursday South Korea's SK bioscience will manufacture a component of the U.S. drug developer's experimental coronavirus vaccine.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.